Claims for Patent: 5,286,637

Summary for Patent: 5,286,637

Title:	Biologically active drug polymer derivatives and method for preparing same
Abstract:	New biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula: wherein R represents a lower alkyl group, n is an integer comprised between 25 and 250, X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, and Z when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH.sub.2 containing drug residue.
Inventor(s):	Veronese; Francesco (Padua, IT), Sartore; Luciana (Padua, IT), Orsolini; Piero (Martigny, CH), Deghenghi; Romano (S.-Cergue, CH)
Assignee:	Debiopharm, S.A. (Lausanne, CH)
Application Number:	08/001,434
Patent Claims:	1. Biologically active drug polymer derivatives having the formula wherein R represents a lower alkyl group, n is an integer between 25 and 250, X when combined with adjacent NH and CO groups represents an amino acid or a dipeptide or tripeptide residue, and Z when combined with the adjacent NH group represents a biologically active peptide or protein or NH or NH.sub.2 containing drug residue. 2. Drug polymer derivatives according to claim 1 wherein R represents a methyl group, n is an integer between 40 and 115, X when combined with adjacent NH and CO groups represents an amino acid residue selected from the group consisting of glycine, phenylanaline, tryptophan and norleucine, or a dipeptide or tripeptide residue selected from Gly-Gly, Arg-Arg, Phe-Arg, Gly-Gly-Arg, Gly-Gly-Phe, and Gly-Leu-Gly-Leu, and Z when combined with the adjacent NH group represents the residue of a biologically active peptide, protein or drug selected from the group consisting of superoxidedismutase, ribonuclease, arginase, asparaginase, urokinase, ampicilline, doxorubicine, N-desmethyl-tamixofen, LHRH and synthetic analogues of same, somatostatin and synthetic analogues of same, calcitonin, interleukin-2, tumor necrosis factor, insulin, IGF-1, natural or recombinant interferon, adenin-arabinoside (ara-A), cytosin-arabinoside (ara-C) and acyclovir. 3. Method for preparing biologically active drug polymer derivatives having the formula (I) as defined in claim 1 which comprises: a) reacting a mono-alkoxy-polyethylene glycol derivative of formula wherein R and n have the definition as indicated in claim 1 with 2,4,5-trichlorphenylchloroformate or 4-nitrophenylchloroformate to obtain the corresponding carbonate; b) reacting the carbonate thus obtained with an amino acid or a di- or tripeptide of formula wherein X is defined as indicated in claim 1 to obtain a compound of formula such that the carbonate is bonded directly to the amino group (--NH.sub.2) of the amino acid or peptide; c) converting the compound of formula (IV) thus obtained into the corresponding succinimidyl ester; and d) finally, reacting the said succinimidyl ester with a biologically active peptide or protein or NH or NH.sub.2 -containing drug of formula wherein R and Z are defined as indicated in claim 1 such that the peptide, protein or drug is bonded to the activated carboxyl function of the ester. 4. Pharmaceutical composition which comprises as an active ingredient at least one biologically active drug polymer derivative of formula (I) as defined in claim 1; and a pharmaceutically acceptable carrier. 5. Pharmaceutical composition according to claim 4 which comprises as active ingredient a biologically active drug polymer derivative of formula (I) wherein R represents a methyl group, n represents an integer between 40 and 115, X when combined with adjacent NH and CO groups represents an amino acid residue selected from the group consisting of glycine, phenylanaline, tryptophan and norleucine, a dipeptide or tripeptide residue selected from Gly-Gly, Arg-Arg, Phe-Arg, Gly-Gly-Arg Gly-Gly-Phe and Gly-Leu-Gly-Leu, and Z when combined with the adjacent NH group represents a biologically active peptide, protein or drug residue selected from the group consisting of superoxidedismutase, ribonuclease, arginase, asparaginase, urokinase, ampicilline, doxorubicine, N-desmethyl-tamoxifen, LHRH and synthetic analogues of same, somatostatin and synthetic analogues of same, calcitonin, interleukin-2, tumor necrosis factor, insulin, IGF-1 natural or recombinant interferon, adenin-arabinoside (ara-A), cytosin-arabinoside (ara-C) and acyclovir. 6. Pharmaceutical composition according to claim 5 which comprises as active ingredient a biologically active drug polymer derivative selected from the group consisting of M-PEG 5000-Gly-superoxidedismutase, M-PEG 5000-Trp-superoxidedismutase, M-PEG 5000-nor-Leu-superoxidedismutase M-PEG 1900-Gly-superoxidedismutase, M-PEG 5000-Gly-arginase, M-PEG 5000-Gly-ribonuclease, M-PEG 5000-Gly-urokinase, M-PEG 5000-Gly-ampicillin, and M-PEG 5000-Gly-doxorubicin wherein M-PEG represents monomethoxy-polyethylene.

Details for Patent 5,286,637

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2011-02-15
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2011-02-15